Autopsy report · NCT01105702

Temodar (Temozolomide), Bevacizumab, Lithium and Radiation for High Grade Glioma

“Due to slow accrual”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 month before it started.
• Ran for about 4 years 11 months before it stopped.
• 28 participants enrolled.
• Results were posted on the registry 7 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

NYU Langone Health

Sponsor type

University, hospital or other

Conditions

Brain Cancer

Interventions

Temozolomide; Bevacizumab; Lithium Carbonate; Radiation

Participants

28

Sites

2

Countries

United States

Trials that died the same way

• Staging Procedures to Diagnose Malignant Pleural Mesothelioma
  “due to low/slow accrual” (94% match in meaning)
• Safety and Activity of Digoxin With Decitabine in Adult AML and MDS
  “Slow accrual” (89% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.